or Try an Advanced Search...

    Her2 Stocks List

    Symbol Grade Name % Change
    GTHX A G1 Therapeutics, Inc. 0.00
    ZYME B Zymeworks Inc. -3.07
    ELVN B Enliven Therapeutics, Inc. -0.79
    PBYI C Puma Biotechnology Inc 3.51
    MRKR C Marker Therapeutics, Inc. -9.63
    ZNTL D Zentalis Pharmaceuticals, Inc. 21.61
    OLMA F Olema Pharmaceuticals, Inc. 0.78
    GLSI F Greenwich LifeSciences, Inc. -0.07
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Cancer Her2/Neu Breast Cancer Treatment Of Breast Cancer Medicine Antiestrogens Epidermal Growth Factor Receptor Estrogen Estrogen Receptor Hormones Protein Kinase Inhibitor Selective Estrogen Receptor Degraders Tyrosine Kinase Receptors Cancer Immunotherapy Cancer Treatment Clinical Medicine Drugs Fulvestrant Immune System

    Related ETFs - A few ETFs which own one or more of the above listed Her2 stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 2.97
    BBC B Virtus LifeSci Biotech Clinical Trials ETF 2.04
    ARB A AltShares Merger Arbitrage ETF 1.72
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 1.07
    EVNT B AltShares Event-Driven ETF 0.77
    View all Her2 ETFs...
    Compare ETFs
    Compare ARB to EVNT Compare CNCR to ARB Compare LABD to EVNT

        Her2 Stocks Recent News

        Date Stock Title
        Nov 1 ZYME Zymeworks Q4 2024 Earnings Preview
        Nov 1 ZYME Zymeworks drops as Wells Fargo cuts on valuation
        Nov 1 ZYME Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year
        Nov 1 ZYME Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation
        Nov 1 ZYME Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
        Oct 31 ZYME Zymeworks GAAP EPS of -$0.39 in-line, revenue of $16M misses by $1.85M
        Oct 31 ZYME Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
        Oct 31 OLMA Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
        Oct 30 ZYME Zymeworks Q3 2024 Earnings Preview
        Oct 28 PBYI 3 US Penny Stocks With Market Caps Under $700M
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Cancer Her2/Neu Breast Cancer Treatment Of Breast Cancer Medicine Antiestrogens Epidermal Growth Factor Receptor Estrogen Estrogen Receptor Hormones Protein Kinase Inhibitor Selective Estrogen Receptor Degraders Tyrosine Kinase Receptors Cancer Immunotherapy Cancer Treatment Clinical Medicine Drugs Fulvestrant Immune System
        Her2

        Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human), is a protein that in humans is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene isolated from avian genome. It is also frequently called HER2 (from human epidermal growth factor receptor 2) or HER2/neu.HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.

        More about Her2
        Browse All Tags